| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.04B | 2.04B | 2.72B | 1.92B | 2.90B | 3.37B |
| Gross Profit | 59.22M | 54.73M | 161.91M | 114.71M | 243.63M | 628.10M |
| EBITDA | -77.16M | -60.25M | 131.05M | -107.06M | 140.91M | 541.36M |
| Net Income | -174.00M | -165.55M | 10.99M | -347.35M | 41.81M | 331.67M |
Balance Sheet | ||||||
| Total Assets | 6.10B | 6.25B | 6.07B | 6.27B | 6.94B | 6.46B |
| Cash, Cash Equivalents and Short-Term Investments | 163.72M | 213.72M | 252.49M | 300.77M | 319.67M | 183.92M |
| Total Debt | 1.45B | 1.36B | 1.05B | 904.95M | 799.98M | 581.41M |
| Total Liabilities | 5.26B | 5.39B | 5.06B | 5.27B | 5.59B | 5.14B |
| Stockholders Equity | 843.88M | 854.50M | 1.01B | 1.00B | 1.35B | 1.32B |
Cash Flow | ||||||
| Free Cash Flow | 136.99M | -2.50M | -30.64M | -166.04M | -155.83M | 218.35M |
| Operating Cash Flow | 175.50M | 36.01M | -28.94M | -165.79M | -151.39M | 232.94M |
| Investing Cash Flow | -58.07M | -63.11M | 16.34M | 47.23M | -104.07M | -34.42M |
| Financing Cash Flow | -269.95M | 48.20M | -26.40M | 95.28M | 315.00M | -345.82M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% | |
56 Neutral | HK$88.01M | -0.63 | -8.38% | ― | -48.96% | -185.64% | |
52 Neutral | HK$310.56M | 6.02 | 2.10% | ― | -14.93% | ― | |
50 Neutral | HK$1.35B | -0.72 | -20.96% | 4.44% | -16.06% | -529.92% | |
47 Neutral | HK$193.95M | -2.64 | -12.31% | ― | -0.09% | 37.33% | |
44 Neutral | HK$208.07M | -1.00 | -19.00% | ― | -21.32% | -715.30% | |
37 Underperform | HK$53.40M | -0.15 | -307.36% | ― | -6.40% | -143.33% |
China Tianbao Group Development Company Limited has announced its intention to provide a corporate guarantee of up to RMB800,000,000 to China Construction Bank Corporation for its subsidiary, Huailai Tianbao Health Care Service Co., Ltd. This guarantee supports a long-term loan aimed at enhancing the subsidiary’s cash flow and facilitating the development of Tianbao Jingbei Health City. The agreement terms are considered fair and beneficial for the company and its shareholders, and the bank involved is independent of the company.
China Tianbao Group Development Company Limited announced the expiration of Mr. Hou Liang’s tenure as an independent non-executive director on October 20, 2025. Mr. Hou has decided not to renew his appointment to focus on other business engagements. His departure leaves the company with a shortfall in the required number of independent non-executive directors and committee members as per the Hong Kong Stock Exchange’s Listing Rules. The company plans to fill the vacancy within three months to comply with these regulations.
China Tianbao Group Development Company Limited has announced the composition of its board of directors and their respective roles within the company. The board includes both executive and independent non-executive directors, with Mr. LI Baotian serving as the Chairman. The board has established five committees, each focusing on different aspects of the company’s governance, such as audit, remuneration, nomination, strategic planning, and investment decisions. This announcement provides clarity on the leadership structure and governance framework, which is crucial for stakeholders to understand the company’s decision-making processes and strategic direction.